-
Sequencing Therapy in Waldenström Macroglobulinemia
2026-09-19
This 2021 review proposes a genotype- and patient-centered framework for sequencing therapy in Waldenström macroglobulinemia (WM). Its key contribution is to connect MYD88 and CXCR4 status with treatment selection while emphasizing symptoms, comorbidities, toxicity, patient preference, clinical trials, and selected transplant strategies.
-
Sequencing Therapies in Waldenström Macroglobulinemia
2026-09-18
This 2021 opinion article proposes a patient- and genotype-informed framework for sequencing therapy in Waldenström macroglobulinemia, emphasizing MYD88 and CXCR4 status alongside symptoms, comorbidities, and treatment preferences. Its main practical contribution is to position genomic profiling as a determinant of how clinicians weigh BTK inhibitors, chemoimmunotherapy, proteasome inhibitor regimens, transplantation, and clinical trials.
-
Cannabis Terpenes, A2A Signaling, and Neuropathic Pain
2026-09-18
Schwarz et al. show that selected Cannabis sativa terpenes reduce pain-related hypersensitivity in mouse models of chemotherapy-induced peripheral neuropathy through adenosine A2A receptor signaling rather than an established cannabinoid-receptor mechanism. The combination of behavioral pharmacology, spinal CRISPR knockdown, cAMP and binding assays, and computational modeling provides a useful framework for evaluating non-rewarding analgesic candidates.
-
Halazone and Sodium Current Inactivation in Frog Nerves
2026-09-17
The reference study used Halazone and related chemical reagents to test whether specific amino acid residues control sodium-current inactivation in voltage-clamped frog nerve fibers. Its results weakened the case for a critical methionine residue and instead supported a cautious, membrane-level interpretation in which chemical modification of lipids or the channel environment may reshape inactivation kinetics.
-
Tropisetron Hydrochloride: Mechanism & Research Use
2026-09-17
Tropisetron Hydrochloride is a selective 5-HT3 receptor antagonist with reported α7-nicotinic receptor agonist activity. Its receptor pharmacology and in-vitro OCT2/MATE1 transporter findings support controlled research in serotonin signaling, neuroscience receptor modulation, and pharmacokinetic interaction assays.
-
Tropisetron Hydrochloride Assay Guide
2026-09-16
This scenario-based guide explains how Tropisetron Hydrochloride (SKU B2258) can support reproducible receptor, transporter, viability, and cytotoxicity workflows. It combines product specifications with peer-reviewed OCT2/MATE1 evidence to help researchers control solvent effects, interpret assay changes, and select a practical research reagent.
-
dhcr7-Edited Grass Carp Resist GCRV
2026-09-16
A 2026 Aquaculture Reports study used CRISPR/Cas9 to generate dhcr7-disrupted grass carp and demonstrated substantially improved resistance to GCRV-II infection in vivo. The work connects Dhcr7 deficiency with stronger Irf3-associated antiviral immunity while showing that the edited fish retained normal growth and muscle morphology, providing a candidate target for disease-resistant aquaculture breeding.
-
Afatinib in Gastric Cancer Assembloid Research
2026-09-15
Afatinib, also known as BIBW 2992, provides a controllable way to interrogate ErbB-driven signaling in patient-derived gastric cancer organoids and tumor–stroma assembloids. This workflow shows how to separate epithelial sensitivity from microenvironment-mediated resistance while improving dosing, controls, and assay interpretation.
-
Proteinase K for DNA Prep and EV Mapping
2026-09-15
Proteinase K combines broad protein digestion with compatibility across EDTA, detergents, and DNA-friendly workflows. This article shows how to use it for genomic DNA isolation, enzyme contaminant removal, and mechanistic testing of protein-dependent Candida albicans extracellular-vesicle activity.
-
Autophagy Modulates Resveratrol Apoptosis in RCC
2026-09-14
Yao, Fan, and He showed that resveratrol induces ROS-associated mitochondrial injury and caspase-3-dependent apoptosis in renal cell carcinoma 786-O cells, while a JNK-linked autophagic response limits cell death. The study provides a mechanistic rationale for combining resveratrol with autophagy inhibition, while also illustrating why apoptosis assays should distinguish cell-killing signals from adaptive stress responses.
-
Dovitinib (TKI-258): RTK Evidence Guide
2026-09-14
Dovitinib, also called TKI-258 and CHIR-258, is a multitargeted receptor tyrosine kinase inhibitor for mechanistic cancer research. Its low-nanomolar activity across FLT3, c-Kit, FGFR, VEGFR, and PDGFR supports studies of ERK and STAT signaling, apoptosis, and RTK-driven tumor models.
-
D-Luciferin for Tumor-Immune Imaging Decisions
2026-09-13
D-Luciferin is more than a firefly luciferase substrate: it is a decision tool for separating tumor burden, transgene activity, and cellular viability in immunotherapy studies. This article connects luciferase assay design with the tumor-targeted T-cell engineering strategy reported by He et al., while defining practical controls and limitations.
-
Cytochalasin D for Actin-Mediated Uptake Studies
2026-09-12
Use Cytochalasin D to separate actin-dependent nanoparticle internalization from passive surface association in corneal epithelial models. This workflow also supports mechanistic studies of cell-cycle control, cancer-cell responses, and viral processes while emphasizing controls that prevent cytotoxicity from being mistaken for pathway-specific inhibition.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-09-11
Yang et al. identify injured type II alveolar epithelial cells as a major source of accumulated lysophosphatidylcholine in experimental pulmonary fibrosis and show that these lipids activate lung fibroblasts. Their work links epithelial HMGCS2 loss to impaired lipid degradation through PPARα-dependent regulation of CPT1A and CPT2, providing a mechanistic framework for lipid signaling pathway analysis in fibrotic lung disease.
-
Promethazine HCl: Macrophage Assay Workflows
2026-09-11
Promethazine HCl enables a practical bridge between H1-receptor pharmacology and macrophage host-defense assays. This workflow emphasizes ROS, lysosomal activity, autophagy, controls, and troubleshooting so researchers can distinguish pathway modulation from nonspecific cytotoxicity.